Sosei CVC
VC Fund
Tokyo, Japan
Sosei CVC is a VC fund in Tokyo focused on Biotechnology and Medical. Sosei CVC is support the creation and growth of life science companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Sosei CVC invests in
Stages Sosei CVC invests in
Countries Sosei CVC invests in
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 2 (29%)
- Pharmaceutical 2 (29%)
- Product Research 2 (29%)
- Biopharma 1 (14%)
Stage
- Funding Round 3 (43%)
- Series A 1 (14%)
- Series B 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Junten Bio
|
JUNTEN BIO is a company is to develop new technologies in the field of regenerative medicine. | $1.8M / Dec 17, 2018 | |
Chromocenter
|
Chromocenter is a next generation biopharmaceuticals Manufacturing company. It uses technologies such as artificial chromosome vectors, mainly for drug discovery such as medical pharmaceuticals | $30.8M / Jul 20, 2018 | |
Noile-Immune Biotech
|
Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy. | $77K / May 31, 2018 | |
StemRIM
|
Stem Rim is a biotechnology company aiming to develop “regenerative medicine”.We are developing drugs based on a new mechanism of action that mobilizes stem cells present in the living body to the injured or diseased tissue without removing them out of the body and induces functional tissue regeneration. | $141.7M / Nov 17, 2017 | |
Stem Cell & Device Laboratory
|
Stem Cell & Device Laboratory is aiming to contribute to a healthy society with new cell application products. | $72.3M / Series B / Oct 17, 2017 | |
Modalis Therapeutics
|
Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. | $127.6M / Series A / Oct 06, 2017 | |
Oligogen
|
Oligogen is a bio-venture that specializes in drug development using stem cell technology.We are studying to treat people who cannot walk due to spinal cord injury. | $15.7M / Aug 10, 2017 |
Co-Investors
SMBC Venture Capital
4 deals together
BiGEN
2 deals together
DCI Partners
2 deals together
Kyogin Lease & Capital
2 deals together
Kyoto University Innovation Capital
2 deals together
Mitsubishi UFJ Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Sosei CVC invest in?
Sosei CVC invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Funding Round and Series A stage. Most of the 7 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sosei CVC last invest?
The most recent investment recorded for Sosei CVC closed in Dec 2018. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
